Scientific Focus
Our Research
Angiomedix is tackling a long‑overlooked cause of ischemia and heart attacks: impaired coronary blood flow without large‑artery blockages—conditions now grouped as INOCA/ANOCA and driven primarily by coronary microvascular dysfunction and coronary vasospasm. Routine tools (ECG, echo, treadmill stress tests, even angiography) often miss these disorders, which helps explain why many symptomatic patients are told their hearts are “normal” despite ongoing ischemia and risk.
Advanced tests like PET or cardiac MRI can detect microvascular disease but not vasospasm and are concentrated at a limited number of centers. The result is delayed or incorrect diagnoses, undertreatment, and excess morbidity and cost.
Angiomedix builds on a decade of clinical research showing that invasive coronary function testing—wire‑based coronary physiology assessment paired with pharmacologic provocation using acetylcholine—accurately distinguishes microvascular disease from vasospasm and steers targeted therapy.
Selected Publications:
Diagnostic Yield and Clinical Utility of Coronary Angiography Versus Coronary
Function Testing in Women With Angina and Nonobstructive Coronary Arteries. Journal of the American Heart Association, e035852 https://doi.org/10.1161/JAHA.124.035852
Comprehensive Management of ANOCA, Part 1—Definition, Patient Population, and Diagnosis JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2023, 82: 1245-1263. PMID: 37704315, DOI: 10.1016/j.jacc.2023.06.043
Evaluating Ischemic Heart Disease in Women: Focus on Angina With Nonobstructive Coronary Arteries (ANOCA). Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3:102195. PMID: 39166160
Long-term outcomes of ischaemia with no obstructive coronary artery disease (INOCA): a systematic review and metaanalysis. Open Heart, 11. https://doi.org/10.1136/openhrt-2024-002852